文献速递呼吸道感染

含利福平或利福喷丁的结核病预防治疗方案完成率、安全性和疗效:个体患者数据网络荟萃分析

Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
PubMed 文献 · Lancet Respir Med · 2023-03-23

结果显示3HP治疗完成率高于4R,但治疗相关不良事件及3-4级不良事件导致停药的风险更高,两组结核病发病率无差异。

要点

  • 3HP方案治疗完成率高于4R,但不良事件导致停药风险更高。
  • 3HP与4R的结核病发病率无差异。
  • 选择预防治疗方案需权衡完成率与安全性。

核心结论

  • 在缺乏直接头对头随机对照试验的情况下,个体患者数据网络荟萃分析提示3HP较4R提高治疗完成率,但不良事件风险更高。

研究设计与样本

  • 个体患者数据网络荟萃分析,检索PubMed 2000年1月1日至2019年3月1日发表的随机对照试验。

主要发现

  • 3HP与4R的结核病发病率无差异。

临床怎么用

  • 选择结核病预防治疗方案时需权衡3HP的高完成率与4R的较低不良事件风险。

局限性

  • 缺乏直接比较3HP与4R的随机对照试验,结果为间接比较。
  • 作者指出研究结果尚需证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment. As these regimens have not been compared directly, we used individual patient data and network meta-analysis methods to compare completion, safety, and efficacy between 3HP and 4R. METHODS: We conducted a network meta-analysis of individual patient data by searching PubMed for randomised controlled trials (RCTs) published between Jan 1, 2000, and Mar 1, 2019. Eligible studies compared 3HP or 4R to 6 months or 9 months of isoniazid and reported treatment completion, adverse events, or incidence of tuberculosis disease. Deidentified individual patient data from eligible studies were provided by study investigators and outcomes were harmonised. Methods for network meta-analysis were used to generate indirect adjusted risk ratios (aRRs) and risk differences (aRDs) with their 95% CIs. FINDINGS: We included 17 572 participants from 14 countries in six trials. In the network meta-analysis, treatment completion was higher for people on 3HP than for those on 4R (aRR 1·06 [95% CI 1·02-1·10]; aRD 0·05 [95% CI 0·02-0·07]). For treatment-related adverse events leading to drug discontinuation, risks were higher for 3HP than for 4R for adverse events of any severity (aRR 2·86 [2·12-4·21]; aRD 0·03 [0·02-0·05]) and for grade 3-4 adverse events (aRR 3·46 [2·09-6·17]; aRD 0·02 [0·01-0·03]). Similar increased risks with 3HP were observed with other definitions of adverse events and were consistent across age groups. No difference in the incidence of tuberculosis disease between 3HP and 4R was found. INTERPRETATION: In the absence of RCTs, our individual patient data network meta-analysis indicates that 3HP provided an increase in treatment completion over 4R, but was associated with a higher risk of adverse events. Although findings should be confirmed, the trade-off between completion and safety must be considered when selecting a regimen for tuberculosis preventive treatment. FUNDING: None. TRANSLATIONS: For the French and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Winters N, Belknap R, Benedetti A, et al. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023. PMID: 36966788. doi:10.1016/S2213-2600(23)00096-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。